GNRH1 and neoplasm: Degarelix was recently studied before prostatectomy but the results were controversial, showing higher intra-tumour levels of dihydrotestosteron compared to LHRH agonist + bicalutamide or degarelix + bicalutamide, generating the hypothesis of unknown mechanisms of action that should be better analyzed in other trials [15].